

Neutralizing Potential of Fab IgG Hybrid Antibody Against Dengue Virus (DENV-1,2,3,4) Expressed on Mesenchymal Stem Cells

by Jola Rahmahani

Submission date: 16-Aug-2021 11:50AM (UTC+0800)

Submission ID: 1631869385

File name: Neutralizing_Potential_of_Fab_IgG_Hybrid_Antibody_Against.pdf (254.21K)

Word count: 5318

Character count: 27958



Neutralizing Potential of Fab IgG Hybrid Antibody Against Dengue Virus (DENV-1,2,3,4) Expressed on Mesenchymal Stem Cells

Mezenkimal Kök Hücreler Üzerinde Dengue Virüsüne Karşı (DENV-1,2,3,4) Fab IgG Hibrit Antikoronun Nötrale Edici Potansiyeli

Fedik A. RANTAM^{1,2,3} , Rahaju ERNAWATI¹ , Jola RAHMAHANI¹ , Eryk HENDRIANTO^{2,3} , Helen SUSILOWATI^{2,3} , Rofiqul A'LA^{4,5} , Rizki Kriestya MAYASARI⁴ , Lia Nur AINI⁴  

¹Virology and Immunology laboratory, Dep of Microbiology, Faculty of Vet Med. Airlangga University, Surabaya, Indonesia

²Stem Cell Research and Development Center, Airlangga University, Surabaya, Indonesia

³Dengue Hemorrhagic Fever (DHF) Laboratory, Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia

⁴Vaccinology and Immunotherapeutica, Faculty of Veterinary Medicine, Airlangga University, Surabaya, Indonesia

⁵Institute of Animal and Plant Quarantine, General Director of Animal Service, Ministry of Agriculture, Indonesia

Cite this article as: Rantam, F.A., Ernawati, R., Rahmahani, J., Hendrianto, E., Susilowati, H., A'la, R., Mayasari, R.K., Aini, L.N., 2018. Neutralizing Potential of Fab IgG Hybrid Antibody Against Dengue Virus (DENV-1,2,3,4) Expressed on Mesenchymal Stem Cells. Acta Vet Eurasia 44: 12-19.

ORCID IDs of the authors: F.A.R. 0000-0001-8182-1465; R.E. 0000-0002-9371-7953; J.R. 0000-0001-9103-3200; E.H. 0000-0001-9723-8098; H.S. 0000-0002-3358-5231; R.A. 0000-0001-6057-2287; R.K.M. 0000-0001-9309-5026; L.N.A. 0000-0002-3465-9618.

Abstract

Dengue is an acute mosquito born viral infections in tropical and subtropical countries, that has been steadily increasing every year. Dengue haemorrhagic fever in Indonesia is caused by all 4 viral serotypes termed as DENV-1, DENV-2, DENV-3, and DENV-4. It is very difficult to treat the disease and there is no effective vaccine to eradicate Dengue virus infections. The aim of this research is to express the antibody fragment gene coding VL and VH of Fab IgG antibody in rat bone marrow mesenchymal stem cells (rat BM-MSCs). The genes were isolated from immunized mice using inactive virus of all dengue serotypes. Then genes were hybridized through ligation and inser-

tion into plasmid pBR322, and transfected into rat BMMSCs. To analytically characterize Fab IgG hybrid binding ability, capacity and specificity, we used immune precipitation, western blotting, neutralization assay, and ELISA. All assays suggested that hybrid Fab IgG antibody have high reactivity and affinity, to efficiently neutralize all Dengue virus serotypes 1,2,3,4. Results of this study show that hybrid Fab IgG antibody can be used as neutralizing agent for the treatment of dengue infections in the future.

Keywords: Dengue virus, FabIgG hybrid antibody, generated expression ratBMMSCs, reactivity, neutralization

Öz

Dengue humması, tropik ve subtropikal ülkelerde sivrisineklerden kaynaklanan akut viral bir enfeksiyon olup, her yıl giderek artmaktadır. Endonezya'daki Dang kanamalı ateşine DENV-1, DENV-2, DENV-3 ve DENV-4 adı verilen 4 viral serotip neden olmaktadır. Hastalığın tedavisi çok zordur ve Dang virüsü enfeksiyonlarını yok etmek için etkili bir aşı yoktur. Bu araştırmanın amacı, sıçan kemik iliği mezenkimal kök hücrelerinde (sıçan BM-MSCs) bulunan Fab IgG antikoronun VL ve VH antikör fragmentini kodlayan geninin açığa çıkarılmasıdır. Genler, tüm dang serotiplerinin inaktif virüsü kullanılarak aşılanmış farelerden izole edilmiştir. Sonrasında genler, ligasyon ve plasmid pBR322 içine gömülmesi yoluyla hibridize edilmiş ve sıçan BMMSC'lerine nakledilmiştir. Analitik olarak Fab IgG'nin

hibrid bağlama yeteneği, kapasitesi ve özgünlüğünü karakterize etmek için; bağışıklık çökeltmesi, western blotting, nötralizasyon testi ve ELISA kullanılmıştır. Bütün deneyler, hibrid Fab IgG antikoronun tüm Dang virüsü serotipleri 1,2,3,4'ü etkili bir şekilde nötrleştirmek için yüksek reaktiviteye ve afiniteye sahip olduğunu ortaya koymaktadır. Bu çalışmanın sonuçları, melez Fab IgG antikoronun gelecekte dang enfeksiyonlarının tedavisinde nötrale edici ajan olarak kullanılabilceğini göstermektedir.

Anahtar kelimeler: Dengue virüsü, Fab IgG hibrid antikör, sıçan kemik iliği mezenkimal kök hücrelerinin ekspresyonu (rat-BMMSC), reaktivite, nötrleştirme

Address for Correspondence: Fedik A. RANTAM - E-mail: fedik.ar@gmail.com

Received Date: 31 December 2016 - Accepted Date: 04 December 2017 - DOI: 10.5152/actavet.2018.004

© Copyright 2018 by Official Acta Veterinaria Eurasia. Available online at www.dergipark.gov.tr/uvfd



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

27

Introduction

Dengue virus, a single stranded RNA virus, has four serotypes with different properties and a homology of 60%-70%. In Indonesia, Dengue virus-infected-humans were found in 1968 in Jakarta and Surabaya, Java Island. Dengue then spread into all provinces. Dengue virus was primarily found in rural areas of Indonesia and in densely populated areas predominantly with serotypes 1, 2, and 3. In recent years, however, four serotypes were found in all provinces (Sumarmo, 1987; Putnak, 2003; Ong et al., 2008). Dengue virus has structural and non-structural protein like envelope protein (E), pre-membrane protein (PrM), non-structural proteins (NS1, NS3, and NS5) that can induce humoral immune response (Henchal and Putnak, 1990; Putnak et al., 2003). Dengue virus recognizes the target cell using E protein containing epitopes that can bind to the receptors of superficial membrane on the cell. Then, the RNA virus penetrates the cytoplasm of the target cell followed by the transcription, translation, and multiplication of the Dengue virus, a late stage of which releases from the cell. (Lai, et al., 2008). Although Dengue virus has properties with relative stability, in between serotypes has been found easy to displace. This caused the dominant serotype to replace the other serotype (Yamanaka, et al., 2011). Dengue virus has preferential affinity to dendritic cells and Langerhans cells and can produce permissive infection only by immature cells. Interferon types 1 and 2 play an important role during infection (Wu, et al., 2000; Sarathy et al., 2015).

Human infections by Dengue viruses have been increasing every year, especially in all provinces of Indonesia and in different countries with different serotypes (Ong, et al., 2008). Besides population density or environment, the other problem is that it is still difficult to find an effective antiviral agent for the treatment of Dengue virus infections, and vaccine development is still under investigation (Fried, et al., 2010). Dengue virus has four serotypes and each have different properties. Some of their proteins can induce protecting antibodies but do not constitute cross protection (Rothman, et al., 2010). On the other hand, during infections, immunoglobulins (Ig) play an important role in protecting people against infection. In this context, immunoglobulin G (IgG) has a special property as a neutralizing antibody in the Dengue virus infection. IgG antibodies are generated following class switching and maturation of the antibody response and thus participate predominantly in the secondary immune response (Meulenbroek and Zeijlmer, 1996; Rantam, et al., 2013). Based on these arguments, the IgG can be used for hyper immune therapy. This research was designed to produce IgG under an expression system using rat bone marrow mesenchymal stem cells (ratBMMSCs, Wistar rat strain). IgG can be secreted as a monomer that is small in size allowing it to easily perfuse tissues. IgG has a molecular weight of about 150 kDa and is made up of four peptide chain. It has two kinds of identical light chains which are 50 kDa and 25 kDa. Thus, a tetrameric quaternary structure makes it very easy to

recognize Dengue virus epitopes with serotype specificity (Biel-feldt-Ohmann, et al., 2001). As such, extracted IgG hybrids can be used for the therapy of future Dengue virus infections. This research serves to express the fragment gene coded VL and VH of the FabIgG antibody in rat bone marrow mesenchymal stem cells (ratBM-MSCs).

Materials and Methods

This study was performed in the DHF Laboratory, Institute of Tropical Disease and Stem Cell Research and Development Center in 2015 and 2016 at Airlangga University, Surabaya, Indonesia. The Dengue virus was from DHF Laboratory, Institute of Tropical Disease Airlangga University, strain ITD UNAIR serotype 1,2,3 and 4.

Mesenchymal stem cells

The bone marrow mesenchymal stem cells (ratBMMSCs) were isolated from the short-term culture of the Wistar rat bone marrow. We performed stem cell isolation from the Wistar rat bone marrow in the stem cell laboratory of Airlangga University under the supervision of the animal ethics team of the veterinary faculty of Airlangga University. To maintain these cells, they were cultured using α -MEM (GIBCO, 12000-022) with 10% Fetal Bovine Serum (FBS) (GIBCO, 10270-106) (Rantam, et al., 2009). After seven passages, these cells were used to express a model of the FabIgG hybrid. For the reactivity assay of the hybrid product to DENV-1,2,3,4, vero cells (kindly supplied from Dr. Eric Van Gorp, Institute of Viroscience, Erasmus Medical Center, Rotterdam University) were used.

Primers

Fusion fragment genes of each Fab-VH and LH of IgG to E protein of DENV-1, 2, 3, and 4 were prepared by PCR methods using various specific primers. Our primer design with reference from NCBI with access number 7073322 for heavy chain and bc094049 for light chain, using BLAST primer at NCBI (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) (Table 1). For Fab-IgG, amino acids 200 residue was amplified from the lymphocytes of mice, which were immunized by mixing (70% adjuvant, 20% antigen, 10% water) the inactive virus strain ITD UNAIR serotype 1, 2, 3 and 4 with Montanide™ ISA 70 VG adjuvant (SEPPIC).

Construction of transfer vector for fusion of heavy and light chains' antibody genes

The template encoding the chimeric construct was selectively amplified using external primers (T3 Promoter, Forward primer GCAATTAACCCTCACTAAAGG, T7 promoter, forward primer TAATACGACTCACTATAGGG, T7 terminator, reverse primer GCTAGTTATTGCTCAGCGG). Each primer contains appropriated restriction sites (Amp and tet) for sub cloning into the GCS vector as competent cells. The resulting PCR fragment genes were ligated into the pBR322 (Geneon, Germany, 100-325), and transferred into ratBMMSCs, which were selected. Next, the hinge, CH2 and CH3 domains (amino acid 200 residue) of rat

Table 1. Primers used to amplify the gene-coded immunoglobuline G

Code	Sequence nucleotide	Function
Forward (F)	5'-TGGGGTTCTCTGAGTCTCTC-3'	Primers for synthesis of cDNA
Reverse (R)	3'-CAGCTCTCAGGGCATTCAAT-5'	
FGH1	5'-AGGTTTCAGCTTCAGCAGTCT-3'	Primers specific for heavy chain
RGH1	3'-CGTAGTAAAAATCCTTTGAACAGTA-5'	
FGH2	5'TGAAGAACTCTGCCGTCTATT-3'	
RGH2	3'-GCACAATTTTCTTGCCACT-5'	
FGL1	5'-GTACCATCTCCACCATC-3'	Primers specific for light chain
RGL1	3'-CTCATTCTGTGAAGCTCT-5'	
FGL2	5'-GTCCAGTCAGAGCCTTTTAT-3'	
RGL2	3'-TGGGGTAGAAGTTGTCAAG-5'	
FGL3	5'-GCCAGTTCTTATGTTACT-3'	
RGL3	3'-GAGAGTGAATCTGTCCAG-5'	
FGH1	5'-AGGTTTCAGCTTCAGCAGTCT-3'	Primers for second round PCR
RGH1	3'-CGTAGTAAAAATCCTTTGAACAGTA-5'	

FablgG were amplified by RT-PCR from cells ratBMMSCs, using the following primers FGH1 and RGH1, as shown in Tabel 1. This PCR product was cloned and inserted into ratBMMSc by using the method modified from Liang and others (1997).

Purification of hybrid FablgG

A modified method (Kihira and Aiba 1992; Leickt, et al., 1998; Huse, et al., 2002) was used to purify the FablgG hybrid. Briefly, after the centrifugation of the supernatant of lysed cells at 23,000 × g (13,000 rpm in SS-34 rotor) at 4°C, the supernatant was filtered using a 0.45-µm filter. Then, the pH of the MAb supernatant was adjusted to 8.0 by dialyzing against PBS using dialysis tubing (Serva, 44144.01). In the meantime, the protein A-Sepharose column was prepared and attached to the fraction collector, and then the column was equilibrated with PBS, pH 8.0, at room temperature. A layer antibody solution was washed into the resin bed column with several volumes of PBS, pH 8.0. It was then eluted with 0.1 M citric acid at pH 6.5. The eluent was collected in vials and dialyzed against PBS, pH 7.3 and was then used for analysis.

Enzyme linked immunosorbent assay (ELISA)

This method was used to analyze the antibody titer of the secreting FablgG hybrid. After coating the ELISA plate with the Dengue virus antigen 10⁷, with each volume well at 100µl, the plate was then incubated for 24 hour at 4°C. It was then washed three times with PBS containing 0.05% Tween 20 (PBST) and blocked with PBST containing 3% of skimmed milk for 1 hour at room temperature. After washing it three times with PBST, 100 µl of the two fold dilutions of ratBMMSc culture supernatants were added to the wells. The plates were then incubated for 1 hour at 37°C and washed four times with PBST. In the next step, 100 µL of 1:1600 dilution of HRP conjugated antimouse FC specific antibody (Invitrogen, 31430). The plate was then

incubated for 1 hour at 37°C. After washing, 100 µL of substrate (Invitrogen, 31430) was added and incubated at room temperature for 15 min. Finally, the absorbance was measured using an ELISA reader at 450 nm (Immuno Mini NJ-2300) (Chu, et al., 1994).

Immunoprecipitation of the FablgG hybrid binding to E protein of Dengue virus

The immunoprecipitation was used to analyze reactivity between the epitope and the FablgG hybrid expressed on ratBMMSCs. Briefly, about 2x10⁷ cells in 0.5 ml DMEM were once for 1 hour to maintain cells so as not to fragment. Then, cells were washed with PBS and lysed by 0.5 ml of ice using an NP-40 lysis buffer (50 mM Tris-buffer pH 7.4, 250 mM NaCl, 5mM EDTA, 0.1% NP-40, plus protease inhibitors) (Merck). After removing the insoluble cell debris by microcentrifugation (11,500 rpm for 1 hour at 4°C), the FablgG hybrids were precipitated by protein G conjugated sheparose beads (Amersham Bioscience, 212-006-168) overnight. The beads were then washed with PBS and re-suspended with a loading buffer containing 0.1M DTT, and heated for 10 min at 75°C. They were then resolved in 10% NuPAGE (Invitrogen, NP0001) with a Morpholinepropanesulfonic acid (MOPS) running buffer. Finally, the FablgG hybrid was mixed with a whole antigen of Dengue virus (strain ITD UNAIR serotype 1, 2, 3 and 4) and after that was immunoprecipitated with an anti-FablgG hybrid (Yoshida, et al., 2010).

Neutralizing of FablgG hybrid to E protein in cell culture

Neutralization assay was performed to determine the neutralizing capacity of purified the FablgG hybrid. Briefly, the FablgG hybrid was incubated with 10³ PFU of the whole Dengue virus (strain ITD UNAIR, DENV-1, 2, 3 and 4). A mixture of the FablgG hybrid and the virus were diluted equally with a ratio of 300µl. After a 1-hour incubation at room temperature, they were then




Figure 1. Prototype of the FabIgG hybrid specific envelope protein of Dengue virus (DENV-1, 2, 3, and 4) infected ratBMMSCs. By using pBR322-plasmid

Table 2. Neutralizing activity of the FabIgG hybrid to all Dengue virus serotypes

Reagent	Dilution	Focus Forming Unit (FFU) (mean of reduction)
Vaccinated positive control serum	1:1	0 (100)
Negative control serum	1:1	100 (0)
The FabIgG hybrid	1:1	0 (100)
	1:2	10
	1:4	21
	1:8	41
	1:16	81

Data Focus Forming Unit assay using Dengue virus serotypes 1, 2, 3, and 4 have shown the average of duplicate assays. The FabIgG hybrid was diluted as shown in Table 2.

inoculated to cell target by ratBMMSc derived from bone marrow stem cells, followed by another incubation at 37°C in a 5% CO₂ incubator for one hour. After the removal of the medium, a growth medium was added and incubated for 6 days at 37°C in a 5% CO₂ incubator. Finally, Dengue viruses released from infected cells were detected by indirect ELISA using conjugated FabIgG labeled with HRP (Invitrogen, SAS-10226). These activities were analyzed using a binding index of virus




Figure 2. a, b. The characterization and culturing of bone marrow mesenchymal stem cells (ratBMMSCs). (a) Cells are already growing 90%. (b) characterization of cells using immunocytochemistry stained with CD105 labeled with FITC

to ratBMSCs, and used Immunoassay. Abstractly cells were infected by strain ITD UNAIR Dengue virus; all serotype then reactivated using hybrid immunoglobulin and then staining using HRP (Pauli, et al., 1984). The neutralizing ability was used and compared with vero cells as positive control.

Results

Characterization of Bone Marrow - Mesenchymal Stem Cells (ratBMMSCs)

The ratBMMSCs cells were expanded in the Petri dish until they grow confluent about 90% as seen in Figure 1 and were char-




Figure 3. a-c. PCR product of a fragment gene coded FablgG -D1, 2, 3, 4 VH and VL. a) PCR product of a fragment gene coded FablgG D1, D2; (b) PCR product of a fragment gene has coded FablgG D3, D4; (c) PCR product of a fragment gene has coded FablgG D1, D2, D3, and D4 of VL




Figure 4. Electrophoresis analysis product of the FablgG hybrid D1, 2, 3, and 4. A. Product electrophoresis was stained by using Silver stain (AgNO3). B. Product electrophoresis was stained by using Coomassie blue. C. Immunoprecipitation of protein E.

acterized using CD105. The results were seen as in Figure 2: a characterization using CD105 was done to make sure the cell was a stem cell because CD105 are cell surface markers for Mesenchymal Stem Cells. The PCR product of the gene coded FablgG as well, as in Figure 3, and showed 600 bp that were used to design the FablgG hybrid expressed in ratBMMSCs.

The cloning product of the gene fragment of FablgG DENV 1, 2, 3 and 4 was inserted into the plasmid pBR322, and was then transfected into ratBMMSc cells by using electrophorator. The results of FablgG expression are shown in Figure 4.

The results of the purification of the FablgG hybrid, those expressed in ratBMMSCs and analyzed using a western blot are shown in Figures 4A, B and C. The FablgG hybrid showed a nearly identical pattern of protein bands under reduced conditions. The protein was found to have a molecular weight of 52 kDa, and seemed like a dominant band, which likely represents the monomer of the FablgG hybrid in Figure 5.

Based on the reactivity of the FablgG hybrid of DENV-1, 2, 3 and 4 to E protein, we designed an analysis on the neutralization




Figure 5. A western blotting analysis of E protein of Dengue virus with different serotypes of DENV-1, 2, 3, and 4 then reacted with the FablgG hybrid, and was stained by using Pierce

effect of the FablgG hybrid expressed using the ratBMMSCs model. The results suggested that the FablgG hybrid can neutralize the Dengue virus serotypes 1, 2, 3 and 4 infected with ratBMMSCs. The whole of the reduction plaque neutralization test (PNRT) potential of IgG hybrid in cells is shown in Figure 6 and Figure 7.




Figure 6. a-d. Neutralization assay using ratBMMSc. The purification of the FabIgG hybrid was performed using IgG-Sepharose affinity chromatography and then reacted with Dengue virus. After 1 hour it was incubated at room temperature and then inoculated into ratBMMSc. Three days after incubation in a 5% CO₂ incubator, prepared cells were analyzed by ELISA. (a) Normal ratBMMSCs. (b) ratBMMSCs inoculated with DENV-1, 2 and DENV-3, 4 with the FabIgG hybrid. (c) Vero cells inoculated with DENV-1, 2 and DENV-3, 4, and with the FabIgG hybrid. (d) Normal vero cells.




Figure 7. Comparison of the neutralizing properties of the FabIgG by plaque neutralization test using ratBMMSCs to DENV-1, 2, 3, and 4 serotypes. The neutralization results using vero cells not shown in this diagram. Two-fold dilutions of the affinity of purified FabIgG collected from the supernatant of culture ratBMMSCs assayed by plaque reduction neutralization tests. BSA is a negative control. A. DENV-1, 2, 3, and 4 inoculated vero cells. B. DENV-1, 2, 3, and 4 inoculated ratBMMSCs

Discussion

In this study, we characterize the ratBMMSCs as shown in Figure 2, and the generated transformed ratBMMSCs that expressed the immunoglobulin (FabIgG) hybrid specific serotype of DEN-1, 2, 3, 4 as shown in Figure 1. The prototype of the hybrid showed that the coding gene of VH and LH immunoglobulin were cloned and ligated with others, that we called the FabIgG hybrid, but the mechanism of integration of genes into the ratBMMSc cells genome was not characterized. Although, the genome of ratBMMSCs may enhance transcription, thereby improving the yield of foreign proteins obtained from transformed cell cultures.

The other tests performed in this research demonstrated a molecule of FabIgG using SDS-PAGE 12% with a molecular weight of 52 kDa as seen in Figure 4. They then analyzed the reactivity of

the hybrid using Western blotting as shown in Figure 5. This reactivity showed that the FabIgG hybrid has a good function since the immunoglobulin hybrid can capture antigens of Dengue virus. These properties of the FabIgG hybrid can recognize antigen especially envelope (E) of all Dengue virus serotypes, because they were designed four hands powerful to capture of different serotypes like in Figure 6. That means these hybrids have potential for the development of passive vaccines for all serotypes of Dengue virus. However, the envelope (E) protein is a major antigen for inducing protective antibody (Ab) responses (Halstead, 1998; 2003) and can avoid the risk of Antibody-Dependent Enhancement (ADE). The strength of both molecule binding sites is in the Fab of variable heavy (VH) and light (VL). This way, they have the possibility of a very easy way to build an interaction with an antigen-antibody complex, which will stimulate immediate reactivity of macrophage to opsonisation. Then, peptide

expression will follow on the superficial membrane cell through the major histocompatibility complex I (MHC I), and then induce cell-mediated immune response through an endocytotic process (Kehry and Castle, 1994). This mechanism may play an important role as a baseline how-to design for a preventive model like a blocking agent (de Carvalho Nicacio, et al., 2000; Gigler et al., 1999; Gould et al., 2005).

If we compare the FabIgG hybrid and the active vaccine tetravalent, the hybrid cannot induce polyclonal antibodies, nor generate an immune system. The hybrid FabIgG, however, have to neutralize viral infections by binding to epitops of E protein of Dengue virus. This model has two kinds of functions. The first is a signaling of complex proteins to activation of cellular and humoral immune response through expression of toll-like receptors (TLR) on the surface membrane of macrophage. This pathway can usually provoke the activation of the CD4⁺ T cell through MHC-II of antigen presenting cells (APC). Secondly, it can be used as neutralizing agent to prevent viral infection. Although, the effectiveness of the hybrid FabIgG is still in trial for certain pathogens (like HIV and Salmonella) (Abaitua, et al., 2006; Tagliabue and Rappuoli, 2008).

The results of the ability of the FabIgG hybrid in neutralizing have shown that the hybrid is good at working with this cell, although the neutralizing level still less than using polyclonal antibodies (data not shown). Based on this data, there is still a need to establish a hybrid model expression using a ratBMMSCs cell system, although we have seen that they can work very well. On the other hand, the goal in this study here would be to provide an antibody that can protect immediately, although all the FabIgG hybrids show similar protective effects at local infection sites or in DENV-infected cell culture.

In conclusion, we have shown in this study that the neutralizing effect provided by the FabIgG hybrid against Dengue virus-infected rat bone marrow mesenchymal stem cell (ratBMMSCs) model do not cross-react with uninfected mesenchymal stem cells. Our findings suggest that the FabIgG hybrid may be an attractive strategy for developing a vaccine against Dengue virus as well as passive vaccine.

Acknowledgements: We are grateful to Dr. Eric Van Gorp, for helpful discussions and for providing Vero cells. Also to our team at Stem Cell Research and Development Center, Laboratory of DHF, Institute of Tropical Disease (ITD). This work was supported by grants from the RUPT Air-langga Univer (DIPA Ditlitabmas at 2015 No. 519/UN3/2015, March, 26, 2015 and No.018/SP2H/LT/DRPM/II/2016, February, 17, 2016).

References

- Abaitua F, Rodríguez, J.R., Garzón, A., Rodríguez, D., Esteban, M. 2006. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN γ . *Virus Res* 116, 11-20. [CrossRef]
- Bielefeldt-Ohmann, H., Meyer, M., Fitzpatrick, D.R., Mackenzie, J.S. 2001. Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. *Virus Res* 73(1), 81-9. [CrossRef]
- Champion, J.M., Kean, R.B., Rupprecht, C.E., Notkins, A.L., Koprowski, H., Dietzschold, B., Hooper, D.C. 2000. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. *J. Immunol. Methods* 235, 81-90. [CrossRef]
- Chu., Y.K., Rossy, C., LeDuc, J.W., Lee, H.W., Schmaljohn, C.S., Dalrymple. 1994. Serological relationship among virus in the hanta virus genus family bunyaviridae virology 198, 196-204
- Cramer, R., 2007. Allergy vaccines: dreams and reality. *Expert Rev Vaccines* 2007 Dec; 6(6), 991-9. [CrossRef]
- de Carvalho Nicacio, C., Lundkvist, A., Sjölander, K.B., Plyusnin, A., Salonen, E.M., Björling, E. 2000. A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. *J Med Virol* 60, 446-454. [CrossRef]
- Fried, J.R., Gibbons, R.V., Kalayanarooj, S., Thomas, S.J., Srikiatkachorn, A., Yoon, I.K., Jarman, R.G., Green, S., Rothman, A.L., Cummings, D.A. 2010. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. *PLoS Negl Trop Dis* 4(3), e617. [CrossRef]
- Gigler A., Dorsch, S., Hemauer, A., Williams, C., Kim, S., Young, N.S., Zolla-Pazner, S., Wolf, H., Gorny M.K., Modrow, S. 1999. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. *J Virol* 73, 1974-1979.
- Gould, L.H., Sui, J., Foellmer, H., Oliphant, T., Wang, T., Ledizet, M., Murakami, A., Noonan, K., Lambeth, C., Kar, K., Anderson, J.F., de Silva, A.M., Diamond, M.S., Koski, R.A., Marasco, W.A., Fikrig, E. 2005. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. *J Virol* 79, 14606-14613. [CrossRef]
- Halstead, S.B. 1998. Pathogenesis of dengue: challenges to molecular biology. *Science* 239, 476-481. [CrossRef]
- Halstead, S.B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. *Adv Virus Res* 60, 421-467. [CrossRef]
- Henchal, E.A., Putnak, J.R. 1990. Dengue viruses. *Clin Microbiol Rev* 3, 376-396. [CrossRef]
- Huse, K., Böhme, H.J., Scholz, G.H. 2002. Purification of antibodies by affinity chromatography. *Journal of Biochemical and Biophysical Methods* 51(3), 217-231. [CrossRef]
- Kehry, M.R., Castle, B.E. 1994. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. *Semin Immunol* 6, 287-294. [CrossRef]
- Kihira, Y., Aiba, S. 1992. Artificial immunoglobulin G-binding protein mimetic to staphylococcal protein A. Its production and application to purification of immunoglobulin G. *J Chromatogr B: Biomed Sci Appl* 597, 277-283.
- Lai, C.Y., Tsai, W.Y., Lin, S.R., Kao, C.L., Hu, H.P., King, C.C., Wu, H.C., Chang, G.J., Wang, W.K. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. *J Virol* 82(13), 6631-6643. [CrossRef]

- Leickt, L., Grubb, A., Ohlson, S. 1998. Screening for weak monoclonal antibodies in hybridoma technology. *J Mol Recognit* 11(1-6), 114-116. [\[CrossRef\]](#)
- Liang, W.Q., Fournier, M.J. 1997. Synthesis of functional eukaryotic ribosomal RNAs in trans: development of a novel in vivo rDNA system for dissecting ribosome biogenesis. *Proc Natl Acad Sci USA* 94, 2864-2868. [\[CrossRef\]](#)
- Meulenbroek, A.J., Zeijlemaker, W.P. 1996. Human IgG subclasses: useful diagnostic markers for immunocompetence. Amsterdam CLB, 1-51.
- Ong, S.H., Yip, J.T., Chen, Y.L., Liu, W., Harun, S., Lystiyarningsih, E., Heriyanto, B., Beckett, C.G., Mitchell, W.P., Hibberd, M.L., Suwandono, A., Vasudevan, S.G., Schreiber, M.J. 2008. Periodic re-emergence of endemic strains with strong epidemic potential—a proposed explanation for the 2004 Indonesian dengue epidemic. *Infect Genet Evol* 8(2), 191-204. [\[CrossRef\]](#)
- Pauli, G., Gregersen, J-P., Ludwig, H. 1984. Plaque/ focus immunoassay: a simple method for detecting antiviral monoclonal or other antibodies and viral antigens in cell. *J Immunol Methods* 74, 337-344. [\[CrossRef\]](#)
- Putnak, R., Fuller, J., Vander Zanden, L., Innis, B.L., Vaughn, D.W. 2003. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. *Am J Trop Med Hyg* 68(4), 469-476.
- Rantam, F.A., Purwati, Soegijanto, S., Susilowati, H., Sudiana, K., Hendrianto, E., Soetijipto. 2013. Analysis of recombinant, multivalent dengue virus containing envelope (E) proteins from serotypes - 1, - 3, and - 4 and expressed in baculovirus. *Trials Vaccinol DOI*: 10.1016/j.trivac.2013.10.001. [\[CrossRef\]](#)
- Rantam, F.A., Ferdiansyah, Nasronudin, Purwati. 2009. *Stem Cell Exploration*. Airlangga University Press, Surabaya, 70-75.
- Rothman, A.L. 2010. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. *Curr Top Microbiol Immunol* 338, 83-98. [\[CrossRef\]](#)
- Sarathy, V.V., White, M., Li, L., Gorder, S.R., Pyles, R.B., Campbell, G.A., Milligan, G.N., Bourne, N., Barrett, A.D. 2015. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. *J Virol* 89(2), 1254-1266. [\[CrossRef\]](#)
- Sui, J., Li, W., Roberts, A., Matthews, L.J., Murakami, A., Vogel, L., Wong, S.K., Subbarao, K., Farzan, M., Marasco, W.A. 2005. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. *J Virol* 79, 5900-5906. [\[CrossRef\]](#)
- Sumarmo, 1987. Dengue haemorrhagic fever in Indonesia. *Southeast Asian J Trop Med Public Health* 18, 269-274.
- Tagliabue, A., Rappuoli, R. 2008. Vaccine adjuvants: the dream becomes real. *Hum Vaccine* 4, 347-349. [\[CrossRef\]](#)
- Wu, S.J., Grouard-Vogel, G., Sun, W., Mascola, J.R., Brachtel, E., Putvatana, R., Louder, M.K., Filgueira, L., Marovich, M.A., Wong, H.K., Blauvelt, A., Murphy, G.S., Robb, M.L., Innes, B.L., Bix, D.L., Hayes, C.G., Frankel, S.S. 2000. Human skin Langerhans cells are targets of dengue virus infection. *Nat Med* 6(7), 816-820. [\[CrossRef\]](#)
- Yamanaka, A., Mulyatno, K.C., Susilowati, H., Hendrianto, E., Ginting, A.P., Sary, D.D., Rantam, F.A., Soegijanto, S., Konishi, E. 2011. Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008–2010. *PLoS One* 6, e27322. [\[CrossRef\]](#)
- Yokoyama, T., Ayabe, S., Miyagi, H., Sugano, T., Otsu, A., Sato, H., Kageyama, S., Fujii, T., Shiraki, K. 2001. Varicella-zoster virus gH:gL contains a structure reactive with the anti-human gamma chain of IgG near the glycosylation site. *J Gen Virol* 82, 331-334. [\[CrossRef\]](#)
- Yoshida, T., Yoshida, R., Ma, B.Y., Mikolajczak, S., Kelvin, D.J., Ochi, A. 2010. A novel mitogen fusion protein against CD40+ cells with potent vaccine adjuvant properties. *Vaccine* 28(21), 3688-3695. [\[CrossRef\]](#)

Neutralizing Potential of Fab IgG Hybrid Antibody Against Dengue Virus (DENV-1,2,3,4) Expressed on Mesenchymal Stem Cells

ORIGINALITY REPORT

19%

SIMILARITY INDEX

14%

INTERNET SOURCES

16%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

- 1 Tetsuya Yoshida, Ryoko Yoshida, Bruce Yong Ma, Sebastian Mikolajczak, David J. Kelvin, Atsuo Ochi. "A novel mitogen fusion protein against CD40+ cells with potent vaccine adjuvant properties", Vaccine, 2010
Publication 3%
- 2 Mary C Guttieri, Carol Bookwalter, Connie Schmaljohn. "Expression of a human, neutralizing monoclonal antibody specific to Puumala virus G2-protein in stably-transformed insect cells", Journal of Immunological Methods, 2000
Publication 1%
- 3 www.freepatentsonline.com
Internet Source 1%
- 4 en.wikipedia.org
Internet Source 1%
- 5 www.ncbi.nlm.nih.gov
Internet Source 1%

6	Michel Solignac, Jean-Marie Cornuet, Dominique Vautrin, Yves Le Conte et al. "The invasive Korea and Japan types of , ectoparasitic mites of the Western honeybee (), are two partly isolated clones ", Proceedings of the Royal Society B: Biological Sciences, 2005 Publication	1 %
7	hdl.handle.net Internet Source	1 %
8	repository.unair.ac.id Internet Source	1 %
9	"SCLERODERMA AND RELATED SYNDROMES", APLAR Journal of Rheumatology, 2006 Publication	1 %
10	iovs.arvojournals.org Internet Source	<1 %
11	www.dtic.mil Internet Source	<1 %
12	Submitted to Universitas Airlangga Student Paper	<1 %
13	d-nb.info Internet Source	<1 %
14	docplayer.net Internet Source	<1 %
15	www.hindawi.com Internet Source	<1 %

<1 %

16

Anita F. Meier, Andrea S. Laimbacher.
"Chapter 6 HSV-1 Amplicon Vectors as
Genetic Vaccines", Springer Science and
Business Media LLC, 2020

Publication

<1 %

17

journals.plos.org

Internet Source

<1 %

18

s3.amazonaws.com

Internet Source

<1 %

19

www.mdpi.com

Internet Source

<1 %

20

iai.asm.org

Internet Source

<1 %

21

Lazuardi Mochamad, Bambang Hermanto.
"High-performance liquid chromatography
ultraviolet-photodiode array detection
method for aflatoxin B1 in cattle feed
supplements", Veterinary World, 2017

Publication

<1 %

22

Lisa Pettersson. "Hantavirus-specific IgA in
saliva and viral antigen in the parotid gland
in patients with hemorrhagic fever with
renal syndrome", Journal of Medical
Virology, 05/2011

Publication

<1 %

23

Martínez Gómez, Julia María, Li Ching Ong, Jian Hang Lam, Siti Amanlina Binte Aman, Eshale Anak Libau, Pei Xuan Lee, Ashley L. St. John, and Sylvie Alonso. "Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage", PLoS Neglected Tropical Diseases, 2016.

Publication

<1 %

24

Murrell, S.. "Review of dengue virus and the development of a vaccine", Biotechnology Advances, 201103/04

Publication

<1 %

25

Y.-T. Yen, H.-C. Chen, Y.-D. Lin, C.-C. Shieh, B. A. Wu-Hsieh. "Enhancement by Tumor Necrosis Factor Alpha of Dengue Virus-Induced Endothelial Cell Production of Reactive Nitrogen and Oxygen Species Is Key to Hemorrhage Development", Journal of Virology, 2008

Publication

<1 %

26

patents.google.com

Internet Source

<1 %

27

www.dovepress.com

Internet Source

<1 %

28

Chukiat Sirivichayakul, Elizabeth A. Barranco-Santana, Inés Esquilin-Rivera, Helen M. L. Oh et al. "Safety and

<1 %

Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study", Journal of Infectious Diseases, 2016

Publication

29 Engstrom, H.A.. "Analysis of the specificity and thermodynamics of the interaction between low affinity antibodies and carbohydrate antigens using fluorescence spectroscopy", Journal of Immunological Methods, 200502

Publication

30 Guttieri, M.C.. "Expression of a human, neutralizing monoclonal antibody specific to Puumala virus G2-protein in stably-transformed insect cells", Journal of Immunological Methods, 20001201

Publication

31 doras.dcu.ie

Internet Source

32 www.fil.ion.ucl.ac.uk

Internet Source

33 www.frontiersin.org

Internet Source

34 "Dengue and Zika: Control and Antiviral Treatment Strategies", Springer Science and Business Media LLC, 2018

Publication

35

Debbie Ching Ping Lee, Rahul Raman,
Nahdiyah Abdul Ghafar, Yadunanda Budigi.
"An antibody engineering platform using
amino acid networks: A case study in
development of antiviral therapeutics",
Antiviral Research, 2021

Publication

<1 %

36

Joshua M. Costin, Elena Zaitseva, Kristen M.
Kahle, Cindo O. Nicholson et al.
"Mechanistic Study of Broadly Neutralizing
Human Monoclonal Antibodies against
Dengue Virus That Target the Fusion Loop",
Journal of Virology, 2013

Publication

<1 %

37

W. D. Crill, G.-J. J. Chang. "Localization and
Characterization of Flavivirus Envelope
Glycoprotein Cross-Reactive Epitopes",
Journal of Virology, 2004

Publication

<1 %

38

idoc.pub
Internet Source

<1 %

39

journals.sagepub.com
Internet Source

<1 %

40

nrronline.org
Internet Source

<1 %

41

oro.open.ac.uk
Internet Source

<1 %

42

www.tandfonline.com
Internet Source

<1 %

43

"Antibody Engineering", Springer Science and Business Media LLC, 2018

Publication

<1 %

44

Kevin C. Kemp, Jill Hows, Craig Donaldson. "Bone marrow-derived mesenchymal stem cells", Leukemia & Lymphoma, 2009

Publication

<1 %

45

Methods in Molecular Biology, 2012.

Publication

<1 %

46

"Human Antibody Therapeutics for Viral Disease", Springer Science and Business Media LLC, 2008

Publication

<1 %

47

www.internationalscholarsjournals.org

Internet Source

<1 %

Exclude quotes Off

Exclude matches Off

Exclude bibliography On